Clinical Trials
6,796 trialsNivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
ADAPT NXT
argenx
ASC4START
Novartis
CairnSurgical Breast Cancer Locator (BCL) Post-Market Study
CairnSurgical, Inc.
TOPAZ-1
AstraZeneca
MK-4280A-007
Merck Sharp & Dohme LLC
BOLSTER
Lisata Therapeutics, Inc.
POM MM 014
Celgene
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
SafeHeal Anastomosis Feasibility Evaluation (SAFE)-2023 Study
SafeHeal Inc
DUBLIN-3
BeyondSpring Pharmaceuticals Inc.
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acerta Pharma BV
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
CARMEN-LC03
Sanofi
MEN-301
NX Development Corp
Viale-a
AbbVie
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
MINT
Amgen
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
Pfizer
KIRMONO
Innate Pharma
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
BELINDA
Novartis
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
Takeda
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
KontRASt-06
Novartis
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
AstraZeneca
KEYNOTE145
Acerta Pharma BV
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
PACIFIC-5
AstraZeneca
MK-3475-01C
Merck Sharp & Dohme LLC
SERENE
Sumitomo Pharma Switzerland GmbH
MK-1026-002
Merck Sharp & Dohme LLC
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
VISUALIZE
Vergent Bioscience, Inc.
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Amgen
MYSTIC
AstraZeneca
Morpheus Lung
Hoffmann-La Roche
MK-3475-689
Merck Sharp & Dohme LLC
DESTINY-B12
AstraZeneca